Stock BGNE BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
148.8 USD -3.50% Intraday chart for BeiGene, Ltd. -2.53% -17.47%
May. 28 BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study MT
May. 28 BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
AQ
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
BU
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
BU
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
BU
BeiGene : Financial Information - Form 8-K
PU
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BU
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BU
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BU
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy
AQ
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BU
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation
AQ
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
BU
BRINGING LIGHT TO THE DARKNESS OF CANCER, BEIGENE NAMED NATIONAL PARTNER OF SURVIVORSHIP AND HOPE FOR THE LEUKEMIA & LYMPHOMA SOCIETY'S LIGHT THE NIGHT
AQ
BeiGene : Material Event - Form 8-K
PU
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
BU
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
BU
New BeiGene Head of Europe, Global Clinical Operations appointed
AQ
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
AQ
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
BU
BeiGene to Present at Upcoming Investor Conferences
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.
  5. Press Releases